Assenagon Asset Management S.A. Cardiff Oncology, Inc. Transaction History

Assenagon Asset Management S.A.

$60.5 Billion
Q2 2025

A detailed history of Assenagon Asset Management S.A. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 67,231 shares of CRDF stock, worth $163,371. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,231

Previous 67,231 -0.0%

Holding current value

$163,371

Previous $211,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 14, 2025	SELL	$2.31 - $5.35 $469,604 - $1.09 Million	-203,292 Reduced 75.15%	67,231 $291,000
Q3 2024 Oct 23, 2024	SELL	$2.05 - $2.77 $1.94 Million - $2.62 Million	-945,399 Reduced 77.75%	270,523 $722,000
Q2 2024 Jul 18, 2024	BUY	$2.22 - $5.89 $2.14 Million - $5.67 Million	962,940 Added 380.64%	1,215,922 $2.7 Million
Q1 2024 Apr 24, 2024	BUY	$1.46 - $5.91 $369,353 - $1.5 Million	252,982 New	252,982 $1.35 Million
Q3 2023 Nov 06, 2023	SELL	$1.38 - $2.18 $80,255 - $126,780	-58,156 Reduced 40.83%	84,272 $117,000
Q2 2023 Jul 25, 2023	SELL	$1.37 - $1.95 $346,015 - $492,503	-252,566 Reduced 63.94%	142,428 $209,000
Q1 2023 Apr 18, 2023	BUY	$1.45 - $2.09 $312,403 - $450,292	215,451 Added 120.0%	394,994 $651,000
Q4 2022 Jan 12, 2023	BUY	$1.22 - $1.66 $15,870 - $21,594	13,009 Added 7.81%	179,543 $251,000
Q3 2022 Oct 27, 2022	BUY	$1.54 - $3.21 $17,469 - $36,414	11,344 Added 7.31%	166,534 $256,000
Q2 2022 Jul 27, 2022	SELL	$1.17 - $2.61 $198,045 - $441,794	-169,270 Reduced 52.17%	155,190 $341,000
Q1 2022 Apr 25, 2022	BUY	$2.11 - $7.25 $684,610 - $2.35 Million	324,460 New	324,460 $805,000
Q3 2021 Oct 19, 2021	SELL	$5.01 - $7.58 $131,096 - $198,345	-26,167 Closed	0 $0
Q2 2021 Jul 15, 2021	BUY	$6.65 - $10.04 $174,010 - $262,716	26,167 New	26,167 $174,000

Others Institutions Holding CRDF

# of Institutions

125

Shares Held

25.8M

Call Options Held

978K

Put Options Held

295K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $105M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account

Assenagon Asset Management S.A. Cardiff Oncology, Inc. Transaction History